Biotech Market Research – Different Approach To Stay Ahead Of Your Competitor

DelveInsight has launched a new report on “ Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030 ”.   DelveInsight's " Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030 "  report delivers an in-depth understanding of the Acute Lymphoblastic Leukemia (ALL), historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.   Some key facts of the Report: 1.        The estimated worldwide annual incidence of adult acute lymphoblastic leukemia is about 1 in 100,000. 2.        In 2019, about 5930 new cases of ALL, in which 3280 were males and 2650 were females. 3.        ALL accounts for less than 1% of all new cancer cases, among which 55% are in males, and 45% are in females. 4.        In 2018, about 3000 children in the US and 5000 children in Europe are diagnosed with

  DelveInsight has announced the addition of a new market research report -  Prostate cancer Market Insight, Epidemiology and Market Forecast -2030  to its portfolio.   Key Highlights The total Prostate Cancer prevalent cases in the 7MM were observed to be 6,742,385 in 2017, and are expected to increase during the study period (2017–2030). The US accounted for the highest number of Prostate Cancer prevalent cases, which is expected to increase by 2030. Among all the treatment modalities,  Zytiga  (abiraterone acetate) and  Xtandi  (enzalutamide) are the cornerstone treatments of mCRPC. The overall Prostate Cancer Market Size in the 7MM is anticipated to increase by 2030 owing to positive results of investigational products and a robust pipeline. Key companies like AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-L